Jorge Monge: It Was An Honor to Take Part in the 3rd EBA Workshop on Rare Blood Provision
Jorge Monge, Head of Immunohematology Lab. Basque Center for Blood Transfusion and Human Tissues (Osakidetza), shared on LinkedIn:
”Twenty years of the Spanish program for rare blood donors.
It was an honor to take part in the 3rd EBA Workshop on Rare Blood Provision, organized by the European Blood Alliance (EBA) in collaboration with the International Society of Blood Transfusion (ISBT) and Osakidetza.
In my presentation — “Twenty years of the Spanish program for rare blood donors” — I shared the journey, achievements, and lessons learned from two decades of building and developing this national program managed within the Sociedad Española de Transfusión Sanguínea (SETS) and coordinated by Eduardo Muñiz.
It’s been a collective effort, made possible thanks to the dedication of professionals across Spain who work every day to support patients with rare blood needs.
If you couldn’t attend, you can now watch my talk here:
- Twenty years of the Spanish program for rare blood donors
And I highly recommend exploring the other inspiring talks from the workshop:
- Rare Blood Provision Workshop”

Stay updated with Hemostasis Today.
-
Nov 27, 2025, 16:00Nathan Connell on WFH AI Summaries from the Global Forum
-
Nov 27, 2025, 15:49Piotr Czempik: Rethinking Coagulation in Acute Liver Dysfunction
-
Nov 27, 2025, 15:35Overwhelmed? A Leader’s Guide from Mark Crowther to Getting Back on Track
-
Nov 27, 2025, 15:10Wolfgang Miesbach’s Top 10 Picks for TTP and Thrombosis from ASH 2025
-
Nov 27, 2025, 14:24ICCBBA’s Executive Director Eoin McGrath Chairs a Dynamic Session on AI, Innovation and Informatics in Transfusion Medicine
-
Nov 27, 2025, 13:26Wolfgang Miesbach’s Top 10 Picks for Bleeding Disorders from ASH 2025
-
Nov 27, 2025, 11:19Priya Prasad Presents a Case of Severe Hypotensive Transfusion Reaction
-
Nov 27, 2025, 04:07Eugene Tang Presents Highlights from UK Stroke Forum 2025
-
Nov 27, 2025, 03:47Michael Makris: I Believe the Time Has Come to Consider Emicizumab Up Front in Persons with Acquired Hemophilia
